Market Access/ News/ News/ News/ News/ Patients/ R&D/ Rare diseases The first lipodystrophy treatment for European patients Piotr Wnuk Lipodystrophy, Metreleptin, Myalept, Myalepta, Novelion Therapeutics 0 Comment Novelion Therapeutics’ Myalepta (metreleptin) developed for the ultra-rare condition lipodystrophy has been approved by the European Commission, giving Share X The first lipodystrophy treatment for European patients https://pharmaphorum.com/news/the-first-lipodystrophy-treatment-for-european-patients/
Lipodystrophy, Metreleptin, Myalept, Myalepta, Novelion Therapeutics
0 Comment
